Immunomedics' Trodelvy Improves Survival in Patients With Pretreated Triple-Negative Breast Cancer

NEW YORK – Immunomedics said on Monday that its antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) met its primary endpoint of progression-free survival in the confirmatory Phase III ASCENT trial of metastatic triple-negative breast cancer patients who did not have brain metastases and had received at least two prior therapies.